Omkostningseffektivitet ved behandling af type 1-diabetes med insulinpumpe

Medicin og biovidenskab

• Subcutaneous Infusions 100%
• Type 1 Diabetes Mellitus 67%
• Cost-Benefit Analysis 65%
• Insulin 51%
• Life Expectancy 50%
• Injections 36%
• Quality of Life 32%
• Costs and Cost Analysis 31%
• Diabetes Complications 25%
• Economics 19%
• Quality-Adjusted Life Years 13%
• Denmark 13%
• Therapeutics 12%
• Incidence 12%
• Hypoglycemic Agents 12%
• Meta-Analysis 9%
• Delivery of Health Care 7%